Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Claw Biotech Holdings LLC has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 actions are distributed across 3 distinct art units, showing a diverse technical range for the company's biotech filings. The prosecution involves 3 distinct examiners, which is equal to the number of 3 pending actions. This distribution requires the company to manage three separate examination styles simultaneously.
TRAN, SUSAN T is the busiest examiner for this company, with 1 pending office action. Because each of the pending actions is assigned to a different examiner in a different art unit, the company faces three unique examination environments. This ratio of actions, examiners, and 3 art units suggests that Claw Biotech Holdings LLC must manage three entirely independent prosecution tracks. Practitioners should focus on the specific requirements of TRAN, SUSAN T and the other examiners within the Biotechnology & Pharmaceuticals area, as the lack of overlap in art units and examiners necessitates a decentralized approach.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, SUSAN T | 1 | 63.0% | +34.8% |
| KIM, DANIELLE A | 1 | 36.6% | +51.9% |
| ALLEY, GENEVIEVE S | 1 | 60.5% | +48.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18986536 | ANTI-PATHOGEN COMPOSITIONS | TRAN, SUSAN T | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18277403 | ANTI-PATHOGENIC LIQUID COMPOSITIONS | KIM, DANIELLE A | 10d overdue |
| 18986536 | ANTI-PATHOGEN COMPOSITIONS | TRAN, SUSAN T | — |
| 18229265 | PATHOGEN ELIMINATING ARTICLE FOR TREATING AGRICULTURAL PRODUCTS AND METHODS OF MANUFACTURING AND USING THE SAME | ALLEY, GENEVIEVE S | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1613 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18986536 | ANTI-PATHOGEN COMPOSITIONS | TRAN, SUSAN T | 1615 | §102§112Other | Non-Final OA | — | Pending | Dec 18, 2024 |
| 18277403 | ANTI-PATHOGENIC LIQUID COMPOSITIONS | KIM, DANIELLE A | 1613 | §103DP | Final Rejection | 10d overdue | Pending | Aug 16, 2023 |
| 18229265 | PATHOGEN ELIMINATING ARTICLE FOR TREATING AGRICULTURAL PRODUCTS AND METHODS OF MANUFACTURING AND USING THE SAME | ALLEY, GENEVIEVE S | 1617 | §103 | Non-Final OA | — | Pending | Aug 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialClaw Biotech Holdings LLC has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Susan T Tran has the most, with 1 of Claw Biotech Holdings LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
